Stocktoria
Arcturus Therapeutics Holdings Inc. ARCT
Arcturus Therapeutics Holdings Inc. (ARCT) earns a Piotroski F-score of 1/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $82.0M at a -80.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.756 |
| Retained earnings / assets | -1.898 |
| EBIT / assets | -0.281 |
| Equity / liabilities | 3.743 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ARCT | Arcturus Therapeutics Holdings Inc. | 1/9 | 0.81 | — | -46.1% |
| NRIX | Nurix Therapeutics, Inc. | 3/9 | 1.2 | — | +54% |
| ETON | Eton Pharmaceuticals, Inc. | 5/9 | -2.05 | — | +104.9% |
| SPRY | ARS Pharmaceuticals, Inc. | 3/9 | -1.13 | — | -5.5% |
| CTMX | CytomX Therapeutics, Inc. | 1/9 | -10.12 | — | -44.8% |
| CYTK | CYTOKINETICS INC | 3/9 | -7.91 | — | +376.6% |
| ABCL | AbCellera Biologics Inc. | 4/9 | 4.67 | — | +160.6% |
About Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
FAQ
Is ARCT financially healthy?
Arcturus Therapeutics Holdings Inc.'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does ARCT pay a dividend?
No, Arcturus Therapeutics Holdings Inc. does not currently pay a dividend.
How profitable is ARCT?
In FY2025, Arcturus Therapeutics Holdings Inc. had a net margin of -80.2% and a return on equity of -30.7%.
What is the analyst price target for ARCT?
The average Wall-Street price target for Arcturus Therapeutics Holdings Inc. is $19.89, about 161.7% above the recent price, from 9 analysts.
Is ARCT a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Arcturus Therapeutics Holdings Inc.: a Piotroski F-score of 1/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.